메뉴 건너뛰기




Volumn 92, Issue 6, 2009, Pages 2054-2057

Altered distribution of plasma platelet-activating factor acetylhydrolase between high-density lipoprotein and low-density lipoprotein in patients with polycystic ovary syndrome

Author keywords

[No Author keywords available]

Indexed keywords

ACETYL HYDROLASE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; THROMBOCYTE ACTIVATING FACTOR DERIVATIVE; UNCLASSIFIED DRUG;

EID: 70749136939     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2009.06.022     Document Type: Article
Times cited : (18)

References (17)
  • 1
    • 47249087287 scopus 로고    scopus 로고
    • Polycystic ovary syndrome in adolescents
    • Franks S. Polycystic ovary syndrome in adolescents. Int J Obes (Lond) 32 (2008) 1035-1041
    • (2008) Int J Obes (Lond) , vol.32 , pp. 1035-1041
    • Franks, S.1
  • 2
    • 4043063685 scopus 로고    scopus 로고
    • Insulin resistance, insulin sensitization and inflammation in polycystic ovarian syndrome
    • Dhindsa G., Bhatia R., Dhindsa M., and Bhatia V. Insulin resistance, insulin sensitization and inflammation in polycystic ovarian syndrome. J Postgrad Med 50 (2004) 140-144
    • (2004) J Postgrad Med , vol.50 , pp. 140-144
    • Dhindsa, G.1    Bhatia, R.2    Dhindsa, M.3    Bhatia, V.4
  • 3
    • 38149113967 scopus 로고    scopus 로고
    • Statins in the treatment of polycystic ovary syndrome
    • Kodaman P.H., and Duleba A.J. Statins in the treatment of polycystic ovary syndrome. Semin Reprod Med 26 (2008) 127-138
    • (2008) Semin Reprod Med , vol.26 , pp. 127-138
    • Kodaman, P.H.1    Duleba, A.J.2
  • 4
    • 38149082597 scopus 로고    scopus 로고
    • Cardiovascular disease risk factors in polycystic ovary syndrome
    • Dokras A. Cardiovascular disease risk factors in polycystic ovary syndrome. Semin Reprod Med 26 (2008) 39-44
    • (2008) Semin Reprod Med , vol.26 , pp. 39-44
    • Dokras, A.1
  • 5
    • 0346725827 scopus 로고    scopus 로고
    • Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome
    • Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group
    • Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 81 (2004) 19-25
    • (2004) Fertil Steril , vol.81 , pp. 19-25
  • 7
    • 35448985807 scopus 로고    scopus 로고
    • Chronic inflammation and elevated homocysteine levels are associated with increased body mass index in women with polycystic ovary syndrome
    • Guzelmeric K., Alkan N., Pirimoglu M., Unal O., and Turan C. Chronic inflammation and elevated homocysteine levels are associated with increased body mass index in women with polycystic ovary syndrome. Gynecol Endocrinol 23 (2007) 505-510
    • (2007) Gynecol Endocrinol , vol.23 , pp. 505-510
    • Guzelmeric, K.1    Alkan, N.2    Pirimoglu, M.3    Unal, O.4    Turan, C.5
  • 8
    • 33745621423 scopus 로고    scopus 로고
    • Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin
    • Diamanti-Kandarakis E., Paterakis T., Alexandraki K., Piperi C., Aessopos A., Katsikis I., et al. Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin. Hum Reprod 21 (2006) 1426-1431
    • (2006) Hum Reprod , vol.21 , pp. 1426-1431
    • Diamanti-Kandarakis, E.1    Paterakis, T.2    Alexandraki, K.3    Piperi, C.4    Aessopos, A.5    Katsikis, I.6
  • 10
    • 33750943178 scopus 로고    scopus 로고
    • Clinical aspects of plasma platelet-activating factor-acetylhydrolase
    • Karasawa K. Clinical aspects of plasma platelet-activating factor-acetylhydrolase. Biochim Biophys Acta 1761 (2006) 1359-1372
    • (2006) Biochim Biophys Acta , vol.1761 , pp. 1359-1372
    • Karasawa, K.1
  • 11
    • 2642567931 scopus 로고    scopus 로고
    • Platelet-activating factor acetylhydrolase: is it good or bad for you?
    • Chen C.H. Platelet-activating factor acetylhydrolase: is it good or bad for you?. Curr Opin Lipidol 15 (2004) 337-341
    • (2004) Curr Opin Lipidol , vol.15 , pp. 337-341
    • Chen, C.H.1
  • 12
    • 0042125177 scopus 로고    scopus 로고
    • Lipoprotein-associated phospholipase A2 (platelet-activating factor acetylhydrolase) and cardiovascular disease
    • Caslake M.J., and Packard C.J. Lipoprotein-associated phospholipase A2 (platelet-activating factor acetylhydrolase) and cardiovascular disease. Curr Opin Lipidol 14 (2003) 347-352
    • (2003) Curr Opin Lipidol , vol.14 , pp. 347-352
    • Caslake, M.J.1    Packard, C.J.2
  • 13
    • 33846635122 scopus 로고    scopus 로고
    • Ratio of LDL- to HDL-associated platelet-activating factor acetylhydrolase may be a marker of inflammation in patients with paroxysmal atrial fibrillation
    • Okamura K., Miura S., Zhang B., Uehara Y., Matsuo K., Kumagai K., et al. Ratio of LDL- to HDL-associated platelet-activating factor acetylhydrolase may be a marker of inflammation in patients with paroxysmal atrial fibrillation. Circ J 71 (2007) 214-219
    • (2007) Circ J , vol.71 , pp. 214-219
    • Okamura, K.1    Miura, S.2    Zhang, B.3    Uehara, Y.4    Matsuo, K.5    Kumagai, K.6
  • 14
    • 0021813187 scopus 로고
    • Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man
    • Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., and Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985) 412-419
    • (1985) Diabetologia , vol.28 , pp. 412-419
    • Matthews, D.R.1    Hosker, J.P.2    Rudenski, A.S.3    Naylor, B.A.4    Treacher, D.F.5    Turner, R.C.6
  • 15
    • 33646432490 scopus 로고    scopus 로고
    • Modulating effects of cholesterol feeding and simvastatin treatment on platelet-activating factor acetylhydrolase activity and lysophosphatidylcholine concentration
    • Zhang B., Fan P., Shimoji E., Itabe H., Miura S., Uehara Y., et al. Modulating effects of cholesterol feeding and simvastatin treatment on platelet-activating factor acetylhydrolase activity and lysophosphatidylcholine concentration. Atherosclerosis 186 (2006) 291-301
    • (2006) Atherosclerosis , vol.186 , pp. 291-301
    • Zhang, B.1    Fan, P.2    Shimoji, E.3    Itabe, H.4    Miura, S.5    Uehara, Y.6
  • 16
    • 0036186708 scopus 로고    scopus 로고
    • Altered distribution of platelet-activating factor-acetylhydrolase activity between LDL and HDL as a function of the severity of hypercholesterolemia
    • Tsimihodimos V., Karabina S.A., Tambaki A.P., Bairaktari E., Miltiadous G., Goudevenos J.A., et al. Altered distribution of platelet-activating factor-acetylhydrolase activity between LDL and HDL as a function of the severity of hypercholesterolemia. J Lipid Res 43 (2002) 256-263
    • (2002) J Lipid Res , vol.43 , pp. 256-263
    • Tsimihodimos, V.1    Karabina, S.A.2    Tambaki, A.P.3    Bairaktari, E.4    Miltiadous, G.5    Goudevenos, J.A.6
  • 17
    • 0242408854 scopus 로고    scopus 로고
    • Effect of hypolipidemic drugs on lipoprotein-associated platelet activating factor acetylhydrolase. Implication for atherosclerosis
    • Eisaf M., and Tselepis A.D. Effect of hypolipidemic drugs on lipoprotein-associated platelet activating factor acetylhydrolase. Implication for atherosclerosis. Biochem Pharmacol 66 (2003) 2069-2073
    • (2003) Biochem Pharmacol , vol.66 , pp. 2069-2073
    • Eisaf, M.1    Tselepis, A.D.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.